537 related articles for article (PubMed ID: 9916783)
1. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.
Ke HZ; Crawford DT; Qi H; Pirie CM; Simmons HA; Chidsey-Frink KL; Chen HK; Jee WS; Thompson DD
Bone; 1999 Jan; 24(1):41-7. PubMed ID: 9916783
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
3. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
4. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
5. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study.
Chen HK; Ke HZ; Jee WS; Ma YF; Pirie CM; Simmons HA; Thompson DD
J Bone Miner Res; 1995 Aug; 10(8):1256-62. PubMed ID: 8585430
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia.
Ke HZ; Shen VW; Qi H; Crawford DT; Wu DD; Liang XG; Chidsey-Frink KL; Pirie CM; Simmons HA; Thompson DD
Bone; 1998 Sep; 23(3):249-55. PubMed ID: 9737347
[TBL] [Abstract][Full Text] [Related]
7. Long-term changes in bone mineral and biomechanical properties of vertebrae and femur in aging, dietary calcium restricted, and/or estrogen-deprived/-replaced rats.
Jiang Y; Zhao J; Genant HK; Dequeker J; Geusens P
J Bone Miner Res; 1997 May; 12(5):820-31. PubMed ID: 9144349
[TBL] [Abstract][Full Text] [Related]
8. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.
Ke HZ; Crawford DT; Qi H; Simmons HA; Owen TA; Paralkar VM; Li M; Lu B; Grasser WA; Cameron KO; Lefker BA; DaSilva-Jardine P; Scott DO; Zhang Q; Tian XY; Jee WS; Brown TA; Thompson DD
J Bone Miner Res; 2006 Apr; 21(4):565-75. PubMed ID: 16598377
[TBL] [Abstract][Full Text] [Related]
9. Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat.
Hodsman AB; Watson PH; Drost D; Holdsworth D; Thornton M; Hock J; Bryant H; Fraher LJ
Bone; 1999 May; 24(5):451-5. PubMed ID: 10321904
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Jee WS; Sato M
J Bone Miner Metab; 2005; 23 Suppl():62-8. PubMed ID: 15984416
[TBL] [Abstract][Full Text] [Related]
11. Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
Otomo H; Sakai A; Ikeda S; Tanaka S; Ito M; Phipps RJ; Nakamura T
J Bone Miner Metab; 2004; 22(5):404-14. PubMed ID: 15316861
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
[TBL] [Abstract][Full Text] [Related]
13. Intermittent treatment of prostaglandin E2 with risedronate is more anabolic than prostaglandin E2 alone in the proximal tibial metaphysis of ovariectomized rats.
Chen HK; Jee WS; Ma YF; Pan Z; McOsker JE; Li XJ
Bone; 1995 Oct; 17(4 Suppl):285S-289S. PubMed ID: 8579930
[TBL] [Abstract][Full Text] [Related]
14. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 prevents ovariectomy-induced cancellous bone loss in rats.
Ke HZ; Li M; Jee WS
Bone Miner; 1992 Oct; 19(1):45-62. PubMed ID: 1422305
[TBL] [Abstract][Full Text] [Related]
16. Additional weight bearing during exercise and estrogen in the rat: the effect on bone mass, turnover, and structure.
Tromp AM; Bravenboer N; Tanck E; Oostlander A; Holzmann PJ; Kostense PJ; Roos JC; Burger EH; Huiskes R; Lips P
Calcif Tissue Int; 2006 Dec; 79(6):404-15. PubMed ID: 17160577
[TBL] [Abstract][Full Text] [Related]
17. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
[TBL] [Abstract][Full Text] [Related]
18. Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Liang HH; Ma YF; Jee WS; Pan Z; Setterberg RB; McOsker JE; Li XJ
Bone; 1995 Oct; 17(4 Suppl):335S-339S. PubMed ID: 8579936
[TBL] [Abstract][Full Text] [Related]
19. Bone responses at various skeletal sites to human parathyroid hormone in ovariectomized rats: effects of long-term administration, withdrawal, and readministration.
Kishi T; Hagino H; Kishimoto H; Nagashima H
Bone; 1998 May; 22(5):515-22. PubMed ID: 9600786
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and biomechanical properties of spine and femur of ovariectomized rats treated with naproxen.
Jiang Y; Zhao J; Genant HK; Dequeker J; Geusens P
Bone; 1998 May; 22(5):509-14. PubMed ID: 9600785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]